Sir: Some pharmaceutical companies price all strengths of a particular medication the same. Medications may also be priced so that 1 larger tablet is less expensive than 2 tablets equaling the same dose. Many tablets are scored for breaking or are easy to cut using commercially available tablet cutters.
Discussion. Sertraline has an elimination half-life of 25 to 26 hours. 1 It is metabolized into the active metabolites desmethylsertraline and N-desmethylsertraline, with half-lives between 66 to 80 hours and 62 to 104 hours, respectively. 2 The long half-life of sertraline overlaps the daily doses and acts to minimize potential fluctuations in blood levels due to any variation in the delivered dose. In addition, taking the 2 pieces from 1 tablet on consecutive days would help minimize dosing inconstancies.
Tablet splitting is effective for reducing pharmaceutical costs and has been used successfully in appropriate patients. 3 Counseling on how to use a tablet cutter may decrease dosage variance. Our pilot study illustrates the mean dose achieved when 5 people split 100-mg sertraline tablets to obtain a 50-mg dose.
Lamotrigine in the Treatment of Depersonalization Disorder
Sir: It has been proposed that excitatory amino acids such as glutamate might be relevant to the pathophysiology of depersonalization. 1 For example, subanesthetic doses of ketamine, whose effects might be mediated through increased glutamate release, can induce many of the subjective experiences characteristic of depersonalization.
2 Furthermore, pretreatment with lamotrigine, a drug reported to inhibit glutamate release, 3 has been found to attenuate these effects of ketamine. 4, 5 We report here on 6 patients with chronic depersonalization disorder in whom treatment with lamotrigine as an add-on therapy brought about a significant clinical improvement.
Method. Eleven patients meeting criteria for DSM-IV depersonalization disorder and diagnosed by means of a semistructured interview using the Present State Examination (PSE) 6 were given lamotrigine as an adjunct to their ongoing medication. All patients had continuous (as opposed to intermittent) depersonalization ranging from 2 to 15 years and had proved resistant to previous pharmacologic treatments. Although 2 patients had a previous history of mood disorders, no affective symptoms were present at the time of diagnosing depersonalization disorder. With 1 exception, all patients were taking selective serotonin reuptake inhibitors (SSRIs) at the time of diagnosis. Lamotrigine was increased gradually over the course of 3 weeks, and its effects were assessed by means of the Dissociative Experiences Scale (DES), 7 its depersonalization subscale (as in Simeon et al. 8 ), and a PSE score. These measures were administered at the time of diagnosis and 1 month later (Table 1) .
Results. Six patients reported subjective beneficial effects ranging from 40% to 80% on a subjective improvement scale. These effects were confirmed by a drop in their PSE score and DES depersonalization subscale score. The other 5 patients in the sample reported no beneficial effect, and their scores on the outcome measures remained unchanged. None of the patients reported side effects. In all cases, improvement occurred on treatment with lamotrigine doses from 200 to 250 mg/day. In regard to comorbidity, the greatest improvement was seen in patients with a history of classic migraine (cases 4, 5, and 6; there were no migraine cases among the nonresponders). An association between depersonalization and migraine has been noted in the literature, 9 and it remains to be seen whether a reported prophylactic effect of lamotrigine on migraine aura might be related to this finding.
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Discussion. This is the first report, to our knowledge, of a beneficial effect of lamotrigine on depersonalization disorder. Although this was an open trial without control for placebo effects, the chronicity of the condition in all 6 cases, coupled with a poor response to previous pharmacologic treatments, makes the positive therapeutic response to lamotrigine augmentation noteworthy and less likely to be due to suggestion or spontaneous remission. Since lamotrigine has been found to have mood stabilizing effects 11 and might be effective in the treatment of posttraumatic stress disorder 12 and borderline personality disorder, 13 caution is needed at this early stage before ascribing the improvement seen in our patients to a specific antidepersonalization effect. However, the fact that patients with depersonalization disorder are notoriously resistant to pharmacologic treatment points to a specific effect of lamotrigine in the treatment of depersonalization disorder and clearly indicates the need for placebo-controlled double-blind trials with lamotrigine both as the sole agent and as an add-on therapy with SSRIs. 1 are to be commended for attempting a large observational study intended to advance the knowledge of the use of atypical antipsychotics under conditions that closely approximate those in the clinic, as opposed to the tightly proscribed circumstances dictated by a clinical study. Paradoxically, the authors undermine their own efforts by standardizing data collection around selected parameters, consequently introducing an ascertainment bias.
The primary finding of the study is that olanzapine is safe and associated with fewer adverse events and extrapyramidal side effects in schizophrenic patients compared with a cohort of schizophrenic patients treated with other neuroleptic therapies. Postmarketing surveillance in significantly larger populations of subjects than could have participated in clinical trials is useful for identifying previously undetected but infrequent adverse events. The authors increased the number of observations in their study beyond what would have been possible in a controlled clinical trial, but failed to identify new safety data. A likely explanation for this is that collection of adverse event information was biased toward the collection of movement disorder events, which are known to be associated with antipsychotics. Therefore, a flaw that has plagued other olanzapine and risperidone comparative studies 2, 3 has similarly confounded the findings of this study.
Although the risperidone mean daily dose used in this naturalistic study (5.4 mg) appears reasonable, actual daily risperidone dosages ranged from 1.5 to 30 mg. The average daily doses of risperidone and olanzapine used in the United States for the treatment of schizophrenia are 4.0 and 14.1 mg, respectively (NDTI June 2001, IMS Health, Plymouth Meeting, Pa.). The 10% to 13% difference in adverse events with risperidone compared with olanzapine could, therefore, be totally accounted for by the use of clinically relevant doses of olanzapine and unrealistically high doses of risperidone.
Other events (e.g., diabetes, weight gain) that are more clinically significant than extrapyramidal symptoms (EPS) with atypical antipsychotics were not systematically examined. For example, multiple reports have described impaired glucose metabolism that in some instances was life-threatening in patients receiving olanzapine. [4] [5] [6] Weight gain, in addition to being associated with excess morbidity and mortality, is also associated with reduced compliance with antipsychotic therapy. 7 This study reported no cases of impaired glucose tolerance despite the large number of patients in the olanzapine group, thus raising the possibility of overreporting, in both groups, of the events for which systematic data collection was performed and of underreporting of other events. The large number of patients and the unequal distribution between olanzapine and nonolanzapine subjects could easily make a clinically insignificant difference appear statistically significant.
The haloperidol dose also appears much larger than that typically used for schizophrenia. EPS would not be unexpected with such large haloperidol doses and would skew the findings in favor of a safety advantage for olanzapine. The finding that 10.2% and 19.9% of patients taking olanzapine and risperidone, respectively, were given anticholinergics, while 36.9% and 49.6%, respectively, were identified as having EPS, again suggests that single ratings of patients on an elevated dose of risperidone were responsible for the differences in EPS and accounts for the apparent better safety profile of olanzapine.
Unfortunately, because of these limitations, this study did not fulfill its potential. Besides identifying, in a naturalistic manner, the larger weight gain associated with olanzapine therapy, this comparison yielded very little in useful clinical observation obtained from an authentically naturalistic experience. performance of the procedure. Obviously, this naturalistic approach may cause underreporting of some adverse events, but, on the other hand, the adverse events reported are probably the most frequent and relevant from a clinical perspective.
Although the UKU Side Effect Rating Scale 2 was used to identify EPS, it is important to note that all adverse events mentioned spontaneously by the patients or elicited in the patient-investigator interviews were recorded. Weight gain was reported with statistically significant difference in the olanzapine group compared with the control group. No cases of impaired glucose tolerance were documented in either the olanzapine or control group.
Contrary to Dr. Masand's subjective opinion that adverse events such as weight gain are more clinically significant than EPS, the results of a study conducted in parallel with EFESO showed that for Spanish psychiatrists, EPS is of greater clinical relevance than weight gain. 3 During the start-up meetings for the EFESO study, participating psychiatrists were asked to assign scores of clinical relevance to each of the adverse effects on a list of the most frequent adverse events of antipsychotics, according to their experience. The scores ranged from 1 (insignificant) to 5 (extremely severe). The researchers considered that weight gain has a lower severity (mean ± SD = 2.6 ± 0.79) than EPS such as dystonia (3.21 ± 0.85), hypokinesia (3.01 ± 0.68), akathisia (3.05 ± 0.77), tremor (2.74 ± 0.68), or hypertonia (3.16 ± 0.75).
We strongly disagree with Dr. Masand's suggestion that the doses of risperidone and haloperidol somehow impeded the study from achieving its "potential." Relying solely on a risperidone dose provided by the manufacturer of risperidone as "data on file" from Janssen, Dr. Masand finds "unrealistically high" the dose of risperidone and suggests that the elevated dose of risperidone may be responsible for the differences in EPS. However, the median risperidone dose in the EFESO study was 6 mg/day, meaning that at least half of the risperidone-treated patients received an average daily dose of 6 mg or less. Further, the mean risperidone dose in the EFESO study was 5.39 mg/day. In studies using naturalistic or flexible-dose ranges, investigators have often found that mean daily doses of risperidone exceeded 6 mg. [4] [5] [6] With respect to haloperidol, Dr. Masand claims that the dose used in the EFESO study (mean dose = 13.64 mg; range, 2-40 mg) " . . . appears much larger than that typically used for schizophrenia." The American Psychiatric Association Practice Guidelines for the Treatment of Patients With Schizophrenia 7 recommend that the effective daily dose of haloperidol is most likely in the range of 5 to 20 mg. However, higher doses are still commonly used. 8 We disagree with Dr. Masand's view of the purpose of postmarketing naturalistic studies. Naturalistic studies are not typically the vehicle by which previously undetected but infrequent adverse events are identified. Rather, such studies are most useful in confirming or revising in a naturalistic setting the incidence and clinical relevance of adverse events reported in previous randomized controlled trials. The EFESO study did just this in confirming that olanzapine-treated patients were less likely to experience EPS than patients treated with other antipsychotics.
In summary, the primary objective of the EFESO study was to assess whether the lower incidence of EPS seen in olanzapine-treated patients in clinical trials was observed in a clinical practice setting. The results of this naturalistic study confirmed those findings. Naturalistic trials may also be useful in demonstrating that a priori perceptions regarding drug utilization and effectiveness may not reflect clinical practice. It appears that in this case, Dr. Masand's perceptions regarding the dose of risperidone used in patients with schizophrenia and subsequent EPS profile are not in agreement with clinical practice in Spain. We would encourage Dr. Masand and other investigators to conduct similar observational prospective and controlled studies using different endpoints in order to improve the knowledge about the performance of drugs in actual practice. Letters to the Editor 831 categories, but there is also some degree of specificity regarding indications, such as serotonergic agents for OCD, dopaminergic/ noradrenergic drugs for smoking cessation and attention-deficit/ hyperactivity disorder, and norepinephrine uptake inhibition for poststroke depression. 2 Moreover, this inaccuracy can be puzzling and misleading for the increasing number of patients who are advised to take an "antidepressant," despite not being at all depressed, subtly implying an additional diagnosis and its unnecessary burden if not properly clarified by the physician. Maybe it is time we called these drugs by their main mechanism of action (i.e., serotonergic agents or enhancers, dual agents, or dopaminergic agonists), or merely say such drug can be used to treat depression if the patient is depressed or social phobia, OCD, nicotine dependence, or whatever may be the case if the patient is not depressed.
